Innate Pharma initiates lymphoma trial

(CercleFinance.com) - Innate Pharma announces that a first patient has been treated in the Phase 1/2 clinical trial evaluating the safety and tolerability of IPH6501 in relapsed and/or refractory CD20-expressing B-cell non-Hodgkin's lymphoma (NHL-B).


This multicenter study plans to enroll up to 184 patients. IPH6501 generates proliferation and activation signals targeted to NK cells, and promotes their cytotoxic activity against CD20-expressing malignant cells.

"IPH6501 represents a promising alternative strategy to T-cell therapies for patients with B-cell non-Hodgkin's lymphoma", emphasizes Sonia Quaratino, Medical Director of Innate Pharma.

Copyright (c) 2024 CercleFinance.com. All rights reserved.